Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
Company earns $750,000 milestone payment related to SWARM-P.a. Study
News provided by
Share this article
Share this article
MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided a corporate update.
First Quarter 2021 and Recent Highlights:
Continued to advance the single ascending dose (SAD) cohort of the SWARM-
P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for cystic fibrosis patients with chronic
Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/ Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch.
US Army taps PPD to conduct PTSD treatment research outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.
By GCN Staff
Feb 26, 2021
To improve the quality of medical care for military service members, researchers are adopting artificial intelligence and markerless motion-capture technology to assess the biomechanical skills of medical trainees and provide feedback for improvement.
“Simulation-based medical skill training, both initial and refresher training, require systematic, objective, high quality trainee evaluation and feedback,” the Army’s Medical Technology Enterprise Consortium said in a request for proposals. Unfortunately, MTEC said, evaluation and feedback on trainees’ performance are currently based on trainers’ standards rather than on an objective skill performance standard.
The Investigating Methods for Performance Overdrive (IMPROVE) program aims to address these assessment challenges. In December 2020, MTEC tapped the Southwest Research Institute (SwRI) to develop a simulation-based training system that compares the physical performance of medical traine
Collaboration with U.S. Army seeks to improve medic training and certification
Triage care on the battlefield requires split-second decision-making and proficiency in providing first aid. Correctly applying a tourniquet or inserting an intubation tube before a patient is evacuated to a hospital could save lives. To improve training for the field medics responsible for this level of care, researchers at Rensselaer Polytechnic Institute will team up with researchers from the United States Army Research Laboratory in Orlando, Florida, to better understand skill acquisition and to standardize the prolonged field care (PFC) certification process.
With the support of a $3.1 million grant from the U.S. Army Combat Capabilities Development Command Soldier Center, the team will combine neuroimaging, computer vision, eye-tracking, and artificial intelligence methods to make PFC certification faster, more objective, and scalable for all soldiers.